skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

15319

Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension



Review

(7370) Total Article Views


Authors: Gautam V Ramani, Myung H Park

Published Date May 2010 Volume 2010:4 Pages 61 - 70
DOI: http://dx.doi.org/10.2147/DDDT.S6208

Gautam V Ramani, Myung H Park

University of Maryland, Baltimore, MD, USA

Abstract: Sildenafil is an orally administered phosphodiesterase type 5 inhibitor that is approved for the treatment of pulmonary arterial hypertension (PAH). The hemodynamic effects of sildenafil are mitigated primarily via potentiating the effects of endogenous nitric oxide, leading to smooth muscle cell relaxation and reductions in pulmonary arterial pressures and pulmonary vascular resistance. When added to standard background therapy in patients with idiopathic or associated PAH from congenital heart disease, anorexigen use, or connective tissue disease, sildenafil treatment results in improved exercise capacity as measured by 6 minute walk distance, improved hemodynamics, and favorable changes in quality of life. Sildenafil use is contraindicated with concomitant nitrate administration, and caution should be exercised when used in combination with antihypertensive agents due to risks of precipitating hypotension. Side effects are generally mild, and include flushing, headaches, and epistaxis. The combination of sildenafil with intravenous epoprostenol is safe and well tolerated, and further improves exercise capacity. Sildenafil is approved only for treatment of PAH, and although emerging data suggest a potential role in treating other types of pulmonary hypertension, larger trials are required to confirm these findings.

Keywords: sildenafil, pulmonary arterial hypertension, phosphodiesterase type 5 inhibitor




Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read: